Dr Reddy's Laboratories (Dr Reddy's Laboratories) Gross Profit : $1,911 Mil (TTM As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Dr Reddy's Laboratories Gross Profit?

Dr Reddy's Laboratories's gross profit for the three months ended in Dec. 2023 was $507 Mil. Dr Reddy's Laboratories's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $1,911 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Dr Reddy's Laboratories's gross profit for the three months ended in Dec. 2023 was $507 Mil. Dr Reddy's Laboratories's Revenue for the three months ended in Dec. 2023 was $867 Mil. Therefore, Dr Reddy's Laboratories's Gross Margin % for the quarter that ended in Dec. 2023 was 58.50%.

Dr Reddy's Laboratories had a gross margin of 58.50% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Dr Reddy's Laboratories was 59.65%. The lowest was 53.10%. And the median was 54.99%.

Dr Reddy's Laboratories Gross Profit Historical Data

The historical data trend for Dr Reddy's Laboratories's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Reddy's Laboratories Gross Profit Chart

Dr Reddy's Laboratories Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Gross Profit

Get a 7-Day Free Trial

1,200.61

1,261.05

1,415.51

1,494.17

1,693.80

Dr Reddy's Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Profit	Get a 7-Day Free Trial															486.13	437.57	481.03	485.95	506.92

Competitive Comparison of Dr Reddy's Laboratories's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dr Reddy's Laboratories's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's Gross Profit distribution charts can be found below:

* The bar in red indicates where Dr Reddy's Laboratories's Gross Profit falls into.

Dr Reddy's Laboratories Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Dr Reddy's Laboratories's Gross Profit for the fiscal year that ended in Mar. 2023 is calculated as

Gross Profit (A: Mar. 2023 )	=	Revenue	-	Cost of Goods Sold
	=	2988.811	-	1295.011
	=	1,694

Dr Reddy's Laboratories's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )	=	Revenue	-	Cost of Goods Sold
	=	866.601	-	359.682
	=	507

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,911 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Dr Reddy's Laboratories's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	507	/	866.601
	=	58.50 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Dr Reddy's Laboratories (NYSE:RDY) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Dr Reddy's Laboratories had a gross margin of 58.50% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Dr Reddy's Laboratories Gross Profit Related Terms

Thank you for viewing the detailed overview of Dr Reddy's Laboratories's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.

Dr Reddy's Laboratories (Dr Reddy's Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (NYSE:RDY) » Definitions » Gross Profit

Traded in Other Exchanges

DRREDDY:India 500124:India RDDA:Germany RDDA:Germany R1DY34:Brazil

Address

8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034

Website

https://www.drreddys.com

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.